DNA methylation changes occur early and broadly during carcinogenesis. Methylscape is a rapid assay that detects global DNA methylation patterns in body fluids (blood, urine, and saliva) and may detect a cancer signal and predict the cancer signal origin (CSO) from a single fluid sample, using the differential interaction between methylated and unmethylated DNA and gold nanoparticles.
This prospective observational study evaluates the diagnostic performance (sensitivity and specificity) of the Methylscape test in Colombian patients with various biopsy-confirmed solid tumors compared with age- and sex-matched cancer-free (healthy) volunteers. The study is conducted in three parts: Phase 1 validates the assay in 250 patients with cancer; Sub-study 2a compares 1,500 patients with cancer against 1,500 matched cancer-free volunteers; and Sub-study 2b uses serial blood and urine sampling in 300 patients with early-stage disease to assess detection of disease relapse during follow-up, in parallel with standard imaging.
The study also estimates positive and negative predictive values (PPV/NPV) and projects the budget impact and cost-effectiveness of Methylscape as a multi-cancer early detection (MCED) tool in an upper-middle-income Latin American setting.
Inclusion Criteria:
Inclusion - Cancer cohort:
Additional criteria - tumor-burden monitoring (Sub-study 2b):
Exclusion Criteria (both cohorts):
acardona@fctic.org+573016348173
Colombian adults (≥18 y) with biopsy-confirmed solid tumors (behavior code 3, ICD-O-3) diagnosed within 90 days and untreated. Provide blood, urine, saliva, and FFPE tumor tissue for Methylscape testing. An early-stage subset is followed with serial blood/urine sampling for relapse detection (Sub-study 2b).
Colombian adults (≥18 y) without cancer diagnosis or treatment in the prior 3 years, matched to cancer patients by sex, age, race/ethnicity, and BMI. Provide blood, urine, and saliva for Methylscape testing (Sub-study 2a).
Analysis of Urinary Methylation Patterns Via Liquid Biopsy as an Early Diagnosis Tool
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Methylation Biomarkers for Pioneering Early Esophageal Cancer Detection
Project CADENCE (CAncer Detected Early caN be CurEd)
Detection of Methylated Reprimo in Plasma for Asymptomatic Gastric Cancer
ProSight: a Multi-centre Interventional Study Evaluating MCED in Asymptomatic Population
Methylated Biomarkers of Smoking as a Selection Tool in Participants for Lung Cancer Screening
DNA Methylation Testing for the Screening of Uterine Cervical Lesion